Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia

Gómez, Raúl; Abad, Antonio; Delgado, Francisco; Tamarit, Silvia; Simón, Carlos; Pellicer, António

doi:10.1016/j.fertnstert.2010.10.024

Cited by 65 publications

(57 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gómez et al [29] conducted a study investigating the effects of the quinagolide on peritoneal endometriosis in 9 hyperprolactinemic women. To our knowledge, this is the first and only study to demonstrate the effects of quinagolide on endometriosis in humans.…”

Section: Discussionmentioning

confidence: 99%

“…In the time period between the pre-and post-treatment laparoscopic procedures, 25-75 µg/day quinagolide was administered orally for 18-20 weeks. Gómez et al [29] found that, by interfering with angiogenesis, enhancing fibrinolysis and reducing inflammation, quinagolide reduces or eliminates peritoneal endometriotic lesions in women with endometriosis. Additionally, histological analyses revealed that this effect was associated with a downregulation of VEGF/VEGFR-2 and pro-angiogenic cytokines within the lesions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Non-Ergot Derived Dopamine Agonist Quinagolide as an Anti-Endometriotic Agent

Akyol¹,

Kavak²,

Akyol

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aim: The study aimed to investigate the efficacy of a dopamine agonist, quinagolide, on experimentally induced endometriosis in a rat model. Methods: Twenty female Wistar rats were used in this experiment. Endometriosis was surgically induced by transplantation of autologous endometrial tissue. A second laparotomy was performed 4 weeks after the first one to assess the pre-treatment implant volumes, and peritoneal lavage with saline solution was performed to assess the peritoneal cytokine levels. Rats were randomized to treatment with quinagolide or saline. At the end of the treatment period, a third laparotomy was performed to compare pre- and post-treatment implant volumes and cytokine levels within the groups. Implants were excised to compare glandular tissue (GT) and stromal tissue (ST) scores between the groups. Results: In the quinagolide group, post-treatment volume was statistically significantly reduced compared with pre-treatment volume (p = 0.01). There were significant decreases in interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) levels in peritoneal fluid samples in quinagolide-treated rats when compared to pre-treatment levels (p = 0.03 and p < 0.01). Histopathologically, both GT and ST scores were significantly lower in the quinagolide group compared to the control group (p = 0.01 and p = 0.02). Conclusions: Quinagolide caused a significant regression in endometriotic implants and it also significantly reduced the levels of IL-6 and VEGF in peritoneal fluid.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Non-Ergot Derived Dopamine Agonist Quinagolide as an Anti-Endometriotic Agent

Akyol¹,

Kavak²,

Akyol

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Nap et al showed that anginex reduces the number of established endometriotic lesions in a mouse model of endometriosis 78 . However, the eff ect of anginex upon reducing endometriosis lesions was modest and it has not been used in clinical trials.…”

Section: Temsirolimusmentioning

confidence: 99%

Novel Medical Treatment Modalities of Endometriosis

Uysal¹,

Caglı²,

Aksoy³

et al. 2015

Kafkas J Med Sci

View full text Add to dashboard Cite

show abstract

“…При назначении хинаголида было отмечено умень-шение размеров очагов на 69,5%; в 35% случаев эндоме-триоидные гетеротопии полностью исчезли [42]. Из по-бочных эффектов терапии только в 1 случае описана рво-та, из-за возникновения которой пациентке пришлось прервать лечение.…”

Section: производные трициклических бензогуанолинов (неэр-голиновые)unclassified

The significance of prolactin in the pathogenesis of genital endometriosis and the possibilities of dopamine agonist therapy

Molotkov¹,

Yarmolinskaya²

2015

Ross. vestn. akush.-ginekol.

View full text Add to dashboard Cite

Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia

Cited by 65 publications

References 42 publications

The Non-Ergot Derived Dopamine Agonist Quinagolide as an Anti-Endometriotic Agent

The Non-Ergot Derived Dopamine Agonist Quinagolide as an Anti-Endometriotic Agent

Novel Medical Treatment Modalities of Endometriosis

The significance of prolactin in the pathogenesis of genital endometriosis and the possibilities of dopamine agonist therapy

Contact Info

Product

Resources

About